Chemical formula: C₁₃H₁₇N₅O₈S₂ Molecular mass: 435.433 g/mol PubChem compound: 5742832
Aztreonam is indicated for:
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Aztreonam is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only minors (0 - 18 years old) , adults (18 years old or older)
Urinary tract infections including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of N. gonorrhoeae.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only minors (0 - 18 years old) , adults (18 years old or older)
Lower respiratory tract infections: including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only minors (0 - 18 years old) , adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only minors (0 - 18 years old) , adults (18 years old or older)
Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Since aztreonam provides only Gram negative cover, it should not be given alone as initial blind therapy, but may be used with an antibiotic active against Gram positive organisms until the results of sensitivity tests are known.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only minors (0 - 18 years old) , adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
